Bevespi Aerosphere (Glycopyrrolate/Formoterol Fum) Patent Expiration, LOE Window & CMS Spending

Bevespi Aerosphere (Glycopyrrolate/Formoterol Fum) by AstraZeneca: FDA Orange Book LOE 2031-03-17, 0 AB generics, $73.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN208294 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-03-17
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$73.6M
2024 Medicare Part D Spend$65.5M
2024 Medicaid Spend$8.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.